CannTrust Holdings Inc (CTST) Given $11.08 Consensus Target Price by Brokerages

Share on StockTwits

CannTrust Holdings Inc (NYSE:CTST) has been assigned an average broker rating score of 1.75 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation, one has given a buy recommendation and two have given a strong buy recommendation to the company. CannTrust’s rating score has declined by 16.7% from three months ago as a result of a number of analysts’ ratings changes.

Brokers have set a twelve-month consensus price target of $11.08 for the company and are expecting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned CannTrust an industry rank of 46 out of 255 based on the ratings given to related companies.

A number of research analysts have issued reports on CTST shares. Zacks Investment Research cut shares of CannTrust from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. Bloom Burton reaffirmed an “accumulate” rating on shares of CannTrust in a report on Friday, March 29th.

Shares of NYSE CTST traded up C$0.45 during midday trading on Friday, reaching C$7.29. 18,683 shares of the company’s stock traded hands, compared to its average volume of 2,418,800. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.54 and a current ratio of 7.65. CannTrust has a one year low of C$4.35 and a one year high of C$11.97. The company has a market cap of $734.20 million, a PE ratio of -66.18 and a beta of 4.40.

CannTrust (NYSE:CTST) last released its quarterly earnings data on Thursday, March 28th. The company reported C($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of C($0.04) by C($0.16). CannTrust had a negative net margin of 28.09% and a negative return on equity of 7.34%. The business had revenue of C$16.20 million for the quarter, compared to the consensus estimate of C$20.99 million. The company’s revenue was up 131.4% compared to the same quarter last year. On average, analysts forecast that CannTrust will post 0.03 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Paragon Capital Management LLC purchased a new position in shares of CannTrust in the first quarter worth $54,000. Virtu Financial LLC purchased a new position in shares of CannTrust in the first quarter worth $618,000. Legacy Advisors LLC purchased a new position in shares of CannTrust in the first quarter worth $1,555,000. Finally, Davis Rea LTD. purchased a new position in shares of CannTrust in the first quarter worth $3,846,000. 0.27% of the stock is owned by institutional investors and hedge funds.

About CannTrust

CannTrust Holdings Inc produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital.

Further Reading: What are retained earnings?

Get a free copy of the Zacks research report on CannTrust (CTST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cyberark Software Ltd  Receives Consensus Rating of “Buy” from Analysts
Cyberark Software Ltd Receives Consensus Rating of “Buy” from Analysts
Fennec Pharmaceuticals Inc  Receives Consensus Rating of “Buy” from Brokerages
Fennec Pharmaceuticals Inc Receives Consensus Rating of “Buy” from Brokerages
Douglas Emmett, Inc.  Receives Consensus Recommendation of “Hold” from Analysts
Douglas Emmett, Inc. Receives Consensus Recommendation of “Hold” from Analysts
Landec Co.  Expected to Announce Quarterly Sales of $149.93 Million
Landec Co. Expected to Announce Quarterly Sales of $149.93 Million
CubeSmart  Expected to Post Earnings of $0.41 Per Share
CubeSmart Expected to Post Earnings of $0.41 Per Share
-$0.33 Earnings Per Share Expected for Achieve Life Sciences Inc  This Quarter
-$0.33 Earnings Per Share Expected for Achieve Life Sciences Inc This Quarter


 
© 2006-2019 Zolmax.